No bull market has grown bigger horns this decade than medical marijuana, and while there’s not as much big pot money to get in on in the
Not only is medical marijuana federally legalized in
The launch of the first marijuana exchange-traded fund (ETF) in
Here are 5 stocks that we think are worth watching closely in the immediate future:
#1 Canopy Growth Corp.
Currently trading with a market cap of
This company is ripe for the legalization of marijuana for recreational use. It’s just announced the licensing of new facilities at its flagship project at
Shares in Canopy Growth jumped 9 percent to
Overall, Canopy has seen its stock rise more than 386 percent in the past year, making it a real ‘unicorn’ (the favored term for start-ups hitting the billion-dollar mark).
#2 Invictus MD (IMH.V; IVITF)
This is another first-and it’s a big one: Invictus is the first licensed medical marijuana company to pay a dividend to shareholders, and it’s also well-prepared for the legalization of recreational marijuana.
We’re watching Invictus closely because it’s been smartly targeting small and mid-size companies with significant growth potential, and its strategy is all about profitability. It’s also not afraid to get down and dirty. Its owners were quietly scooping up ‘pick and shovel’ assets to lower the costs of its marijuana production, and just waiting for a big reason to draw everyone’s attention: Legalization of recreational use will do it.
And the kicker: In December they paid their shareholders
Recently, they’ve made some game-changing acquisitions valued at some
In
The catalysts keep mounting for this small-cap with large-cap savvy.
#3 GW Pharmaceuticals
If you’re not ready for a cannabis producer-despite the major Canadian catalysts-this cannabinoid-based drug developer is a good bet, even State side because these companies aren’t likely to be negatively affected by the Trump administration’s indications that it’s not marijuana-friendly.
GW Pharmaceuticals is a biopharmaceutical company that develops and commercializes therapeutics using a proprietary cannabinoid product platform.
This company has a
#4
If you’re wondering why big pharma isn’t cashing in on the medical marijuana bonanza, this is why: They’re sitting on the sidelines right now. Why re-invent the wheel? They bide their time letting the ambitious small-caps spend all the cash with development and clinical trials. Once it’s all across the finish line, they will swoop in and buy them up. They won’t compete with them. They will own them-eventually, so there’s no need to dabble in this until it’s all solid. For now, though big pharma is bent on blocking progress in terms of legalization of recreational marijuana, but this is smoke and mirrors-they’re just buying time, with some working on synthetic strains of marijuana.
Given the momentum particularly in
So we start with
#5
This drug maker offers sizzling dividends, and its growth picture looks very solid, for the first time in a long time.
What is most likely
More than any other, this company is set up with cash that will allow it to take advantage of any really good acquisition opportunities. Even amid still competition and tough patent battles,
Honorable Mentions? Of course:
- Aphria Inc.-this is the second biggest cannabis producer in
Canada , and it’s only recently been put onCanada’s index funds. - Aurora Cannabis Inc. – another Canadian cannabis giant-in-the-making, this company could give Canopy Growth a run for its money.
Merck (NYSE : MRK)-this drug industry leader is on the bounce-back. The some$170-billion market-cap company’s Keytrude drug, which won approval for treating melanoma in 2014, could reach peak annual sales of$8 billion , and the stock is up some 20 percent since Q1 2016. And it’s got more in the pipeline.Johnson & Johnson (NYSE : JNJ), Novartis (NYSE : NVS), and Roche also all have very hot pipelines. JNJ probably has the biggest pipeline, and Novartis’ cancer portfolio is looking extremely attractive. Roche has about 150 products in development.- Canadian
Knight Therapeutics (TSX: GUD) has beat analyst expectations (in Q1 2017), earning$7.9-million on revenue of$1.8-million -compared to$300,000 it reported in the same period last year. Still needs more in the development pipeline, though. (Market cap,CAD$1.45 billion ) - ProMetic Life Sciences Inc.-this
CAD$1.4 billion -market cap company has just remedied its financing overhang, and also got a boost from a$9.5-million purchase order.
By
Legal Disclaimer/Disclosure from OilPrice.com: This piece is an advertorial and has been paid for. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of Oilprice.com only and are subject to change without notice. Oilprice.com assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report. All content contained herein is subject to the terms and conditions set forth in the original article posted on Oilprice.com and subject to the terms and conditions therein.
DISCLAIMER: OilPrice.com is Source of all content listed above.
FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the
Contact Information:
Media Contact e-mail:
editor@financialnewsmedia.com
SOURCE OilPrice.com
Protea Announces 2016 Year End Results
Frankly Reports Fourth Quarter and Full Year 2016 Financial Results
More Articles